Is Erbaven (generic name) safe to use during pregnancy?

Erbaven (Aspirin) Safety During Pregnancy

Erbaven (aspirin) should not be used during pregnancy, especially during the third trimester, due to risks of fetal harm and complications during delivery. 1

Safety Profile and Risks

• Erbaven (aspirin) is contraindicated during the last 3 months of pregnancy unless specifically directed by a doctor, as it may cause problems in the unborn child or complications during delivery 1
• The FDA drug label explicitly warns that pregnant women should consult a healthcare professional before using this medication 1
• Aspirin belongs to the nonsteroidal anti-inflammatory drug (NSAID) class, which carries risks of stomach bleeding and other adverse effects that may be particularly concerning during pregnancy 1

Specific Concerns in Pregnancy

• NSAIDs like aspirin can cause premature closure of the ductus arteriosus in the fetus, particularly when used in the third trimester 2
• The FDA categorizes aspirin as having "positive evidence of human fetal risk," though benefits may outweigh risks in certain life-threatening situations 2
• Medication use during pregnancy requires careful consideration of maternal benefit versus potential fetal harm 2

Alternative Approaches

• For pain management during pregnancy, non-pharmacological approaches should be considered first 3
• If medication is necessary, consult with an obstetrician to determine the safest option based on the specific indication 2
• Over-the-counter medications are often perceived as safe but can cross the placenta and accumulate in the fetus, potentially causing harm 4

Special Considerations

• If Erbaven was taken before pregnancy was confirmed, discontinuation is advised and consultation with a healthcare provider is recommended 1
• The developing fetus has limited ability to metabolize and eliminate drugs, making it particularly vulnerable to medication effects 4
• The safety profile of medications during pregnancy should be evaluated based on the most current evidence and individual risk-benefit assessment 5

Monitoring and Management

• If exposure to Erbaven has occurred during pregnancy, additional fetal monitoring may be warranted 6
• Detailed ultrasound examination for structural anomalies and growth restriction should be considered following inadvertent exposure 6
• Documentation of exposure timing, duration, and dosage is important for risk assessment 3

Regulatory Guidance

• The FDA drug label for Erbaven explicitly states that pregnant women should consult healthcare professionals before use 1
• Medications with known teratogenic or fetotoxic effects are designated as "contraindicated" during pregnancy 3
• Drug safety in pregnancy requires continuous collection of observational data to assess risks as precisely as possible 3